Skip to main content

An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread

Trial Status: Active

The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986207 by itself, in combination with Nivolumab, and in combination with both nivolumab and ipilimumab in participants with solid cancers that are advanced or have spread.

Inclusion Criteria

  • Participant must consent for pretreatment and on treatment tumor biopsy samples
  • For Part 1C tumor biopsies are optional
  • Nonsmall cell lung cancer (NSCLC) without prior treatment in the advanced or metastatic setting (Part 2C)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Must have received, and progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting (Part 1A, 1B and 1C)
  • Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria; radiographic tumor assessment performed within 28 days before randomization

Exclusion Criteria

  • Primary central nervous system (CNS) disease, or tumors with CNS metastases as the only site of disease. Controlled brain metastases will be allowed to enroll
  • Other active malignancy requiring concurrent intervention
  • Uncontrolled/significant heart disease
  • History of chronic hepatitis [except for hepatocellular carcinoma (HCC)]
  • Active, known, or suspected autoimmune disease

New Jersey

Hackensack University Medical Center
Status: ACTIVE

New York

New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: ACTIVE


Fox Chase Cancer Center
Status: ACTIVE
University of Pennsylvania / Abramson Cancer Center
University of Pittsburgh Cancer Institute (UPCI)
Status: ACTIVE


Salt Lake City
Huntsman Cancer Institute / University of Utah
Status: ACTIVE

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

  • Primary ID CA020-002
  • Secondary IDs NCI-2017-00261, 2016-002263-34
  • ID NCT02913313